Contemporary Pediatrics, Digital Edition, September 2011

Review some of the top stories from the Contemporary Pediatrics website over the last week, and catch up on anything you may have missed.

In a recent study, increased rates of precocious puberty were observed during the COVID-19 pandemic compared to prior years.

Positive topline results from a pair of identical phase 3 trials support the submission of a supplemental New Drug Application to the FDA for Arcutis Biotherapeutics’ roflumilast cream 0.15%, a once-daily topical to treat mild to moderate atopic dermatitis (AD) in children 6 years or older.

Based on recent positive phase 3 results, Arcutis Biotherapeutics,. intends to submit a supplemental New Drug Application with the FDA for roflumilast cream 0.05% to treat mild to moderate atopic dermatitis in children aged 2 to 5 years.